The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics
暂无分享,去创建一个
Ruili Huang | Noel Southall | Yuhong Wang | Adam Yasgar | P. Shinn | A. Jadhav | Dac-Trung Nguyen | C. Austin
[1] E. Gibson,et al. The Serotonergic Appetite Suppressant Fenfluramine , 1999 .
[2] The serotonergic appetite suppressant fenfluramine. Reappraisal and rejection. , 1999, Advances in experimental medicine and biology.
[3] J. Griffin. Prepulsid withdrawn from UK & US markets. , 2000, Adverse drug reactions and toxicological reviews.
[4] J. Jacobson. Thalidomide: a remarkable comeback , 2000, Expert opinion on pharmacotherapy.
[5] Griffin Jp. Prepulsid withdrawn from UK & US markets. , 2000 .
[6] Jon Glasby Ba. A betrayal of trust? , 2012, Nursing older people.
[7] Christopher P Austin,et al. The impact of the completed human genome sequence on the development of novel therapeutics for human disease. , 2004, Annual review of medicine.
[8] R. Dabbah,et al. The Value of USP Public Standards for Therapeutic Products , 2004, Pharmaceutical Research.
[9] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[10] P. Fisher,et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.
[11] Screening existing drugs for neurodegeneration: The National Institute of Neurologic Disorders and Stroke (NINDS) model. , 2005, Retina.
[12] D. Wysowski,et al. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.
[13] M. Feinberg,et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases , 2005, Nature Medicine.
[14] J. Lexchin. Drug withdrawals from the Canadian market for safety reasons, 1963–2004 , 2005, Canadian Medical Association Journal.
[15] Adam Yasgar,et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[16] J. McNeil,et al. Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity , 2006, Drug safety.
[17] Jun O. Liu,et al. A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.
[18] H. Ghofrani,et al. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.
[19] C. Chong,et al. New uses for old drugs , 2007, Nature.
[20] S. Colan,et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. , 2007, American heart journal.
[21] J. DiMasi,et al. The cost of biopharmaceutical R&D: is biotech different? , 2007 .
[22] M. Blommel,et al. Pregabalin: an antiepileptic agent useful for neuropathic pain. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[23] Ruili Huang,et al. Fluorescence spectroscopic profiling of compound libraries. , 2008, Journal of medicinal chemistry.
[24] Christopher P Austin,et al. Characterization of chemical libraries for luciferase inhibitory activity. , 2008, Journal of medicinal chemistry.
[25] Philip J Mease,et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. , 2008, The Journal of rheumatology.
[26] M. Spaeth. Is pregabalin a safe and effective treatment for patients with fibromyalgia? , 2008, Nature Clinical Practice Rheumatology.
[27] David S. Wishart,et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..
[28] S. Ōmura. Ivermectin: 25 years and still going strong. , 2008, International journal of antimicrobial agents.
[29] G J Ebrahim,et al. Neglected tropical diseases , 2005, BMJ : British Medical Journal.
[30] Robert J Kavlock,et al. Toxicity Testing in the 21st Century: Implications for Human Health Risk Assessment , 2009, Risk analysis : an official publication of the Society for Risk Analysis.
[31] Ruili Huang,et al. The pilot phase of the NIH Chemical Genomics Center. , 2009, Current topics in medicinal chemistry.
[32] Christopher P Austin,et al. Monitoring Compound Integrity With Cytochrome P450 Assays and qHTS , 2009, Journal of biomolecular screening.
[33] Melvin E Andersen,et al. Toxicity Testing in the 21st Century: Implications for Human Health Risk Assessment , 2009, Risk analysis : an official publication of the Society for Risk Analysis.
[34] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[35] Toshihiko Ogura,et al. Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.
[36] Ruili Huang,et al. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. , 2010, Biochemical pharmacology.
[37] 王林,et al. Office of Rare Diseases Research , 2011 .
[38] Ruili Huang,et al. Identification of Clinically Used Drugs That Activate Pregnane X Receptors , 2011, Drug Metabolism and Disposition.